Erratum: Difference in association of obesity With prostate cancer risk between US African American and non-Hispanic white men in the selenium and vitamin E cancer prevention trial (SELECT) (JAMA Oncology (2015) DOI: 10.1001/jamaoncol.2015.0513);Difference in association of obesity with prostate cancer risk between US African American and non-Hispanic white men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

JAMA Oncology

Volumn 1, Issue 3, 2015, Pages 342-349

  Barrington, Wendy E ^a,b   Schenk, Jeannette M ^b   Etzioni, Ruth ^a,b   Arnold, Kathryn B ^b   Neuhouser, Marian L ^b   Thompson, Ian M ^c   Lucia, M Scott ^d   Kristal, Alan R ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; SELENIUM;

AFRICAN AMERICAN; AGED; BODY MASS; CANADA; CAUCASIAN; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; EPIDEMIOLOGY; ETHNOLOGY; HEALTH DISPARITY; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MULTICENTER STUDY; OBESITY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; PUERTO RICO; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

AFRICAN AMERICANS; AGED; ANTICARCINOGENIC AGENTS; BODY MASS INDEX; CANADA; CHI-SQUARE DISTRIBUTION; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTH STATUS DISPARITIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OBESITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; PUERTO RICO; RISK ASSESSMENT; RISK FACTORS; SELENIUM; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VITAMIN E;

EID: 84994509791     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.1791     Document Type: Erratum

References (43)

1. Grönberg H. Prostate cancer epidemiology. Lancet. 2003;361(9360):859-864.
2. Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer. 2004;101(10)(suppl):2371-2490.
3. Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol. 2007;177(2):444-449.
4. Gaines AR, Turner EL, Moorman PG, et al. The association between race and prostate cancer risk on initial biopsy in an equal access, multiethnic cohort. Cancer Causes Control. 2014;25(8):1029-1035.
5. Martin DN, Starks AM, Ambs S. Biological determinants of health disparities in prostate cancer. Curr Opin Oncol. 2013;25(3):235-241.
6. Mordukhovich I, Reiter PL, Backes DM, et al. A review of African American-white differences in risk factors for cancer: prostate cancer. Cancer Causes Control. 2011;22(3):341-357.
7. Office of the Surgeon General; Office of Disease Prevention and Health Promotion; Centers for Disease Control and Prevention; National Institutes of Health. The Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity. Rockville, MD: US Department of Health and Human Services, Public Health Service, Office of the Surgeon General; 2001: sect 1. http://www.ncbi.nlm.nih.gov/books/NBK44210/. Accessed March 13, 2015.
8. Wang Y, Beydoun MA. The obesity epidemic in the United States-gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev. 2007;29:6-28.
9. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311(8):806-814.
10. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013;2013:291546.
11. Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med. 2010;61:301-316.
12. Parekh N, Lin Y, Dipaola RS, Marcella S, Lu-Yao G. Obesity and prostate cancer detection: insights from three national surveys. Am J Med. 2010;123(9):829-835.
13. Hu MB, Liu SH, Jiang HW, Bai PD, Ding Q. Obesity affects the biopsy-mediated detection of prostate cancer, particularly high-grade prostate cancer: a dose-response meta-analysis of 29,464 patients. PLoS One. 2014;9(9):e106677.
14. Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer-a dose-response meta-analysis of prospective studies. Ann Oncol. 2012;23(7):1665-1671.
15. Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1977-1983.
16. Jackson MD, Walker SP, Simpson CM, et al. Body size and risk of prostate cancer in Jamaican men. Cancer Causes Control. 2010;21(6):909-917.
17. Nemesure B, Wu SY, Hennis A, Leske MC; Prostate Cancer in a Black Population (PCBP) Study Group. Central adiposity and prostate cancer in a black population. Cancer Epidemiol Biomarkers Prev. 2012;21(5):851-858.
18. Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer. 2007;109(5):875-881.
19. Hayes RB, Ziegler RG, Gridley G, et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev. 1999;8(1):25-34.
20. Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549-1556.
21. Lippman SM, Goodman PJ, Klein EA, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst. 2005;97(2):94-102.
22. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301(1):39-51.
23. World Health Organization. Obesity and Overweight. Fact sheet No. 311. http://www.who.int/mediacentre/factsheets/fs311/en/. Updated January 2015. Accessed March 12, 2015.
24. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol. 1992;23(3):273-279.
25. Polednak AP. Estimating the number of US incident cancers attributable to obesity and the impact on temporal trends in incidence rates for obesity-related cancers. Cancer Detect Prev. 2008;32(3):190-199.
26. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30(2):195-200.
27. Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL Jr, Freedland SJ. Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2936-2942.
28. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2011;4(4):486-501.
29. Kristal AR, Lampe JW. Prioritization of diet and cancer manuscripts: a brief primer. Cancer Epidemiol Biomarkers Prev. 2011;20(5):725-726.
30. Gurel B, Lucia MS, Thompson IM Jr, et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2014;23(5):847-856.
31. Beasley LE, Koster A, Newman AB, et al; Health ABC study. Inflammation and race and gender differences in computerized tomography-measured adipose depots. Obesity (Silver Spring). 2009;17(5):1062-1069.
32. Hsing AW, Chua S Jr, Gao YT, et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst. 2001;93(10):783-789.
33. Velasquez-Mieyer PA, Cowan PA, Umpierrez GE, Lustig RH, Cashion AK, Burghen GA. Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects. Int J Obes Relat Metab Disord. 2003;27(11):1359-1364.
34. Powell IJ, Bollig-Fischer A. Minireview: the molecular and genomic basis for prostate cancer health disparities. Mol Endocrinol. 2013;27(6):879-891.
35. Farrell J, Petrovics G, McLeod DG, Srivastava S. Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. Int J Mol Sci. 2013;14(8):15510-15531.
36. Fowke JH, Signorello LB, Chang SS, et al. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer. 2006;107(10):2361-2367.
37. Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer. 2006;106(2):320-328.
38. Culp S, Porter M. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men. BJU Int. 2009;104(10):1457-1461.
39. Baillargeon J, Pollock BH, Kristal AR, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer. 2005;103(5):1092-1095.
40. Bañez LL, Hamilton RJ, Partin AW, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007;298(19):2275-2280.
41. Werny DM, Thompson T, Saraiya M, et al. Obesity is negatively associated with prostate-specific antigen in US men, 2001-2004. Cancer Epidemiol Biomarkers Prev. 2007;16(1):70-76.
42. Schwenzer NF, Machann J, Schraml C, et al. Quantitative analysis of adipose tissue in single transverse slices for estimation of volumes of relevant fat tissue compartments: a study in a large cohort of subjects at risk for type 2 diabetes by MRI with comparison to anthropometric data. Invest Radiol. 2010;45(12):788-794.
43. Okorodudu DO, Jumean MF, Montori VM, et al. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes (Lond). 2010;34(5):791-799.